Researchers in Catalonia have described an epigenetic mechanism responsible for the activation of a cellular receptor in hepatocellular carcinoma, the IGF2 factor, with samples from 228 patients. This alteration is present in 15% of the tumors; A monoclonal antibody effectively blocks it and slows tumor progression in animal models. More info.